Journal: Oncotarget

Article Title: Inhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition

doi: 10.18632/oncotarget.8842

Figure Lengend Snippet: A. Double immunofluorescence staining of antibodies to CD31 (Red) with antibodies to S100A4/FSP-1(Green) and α-SMA (green) in coronary arterioles of all groups mouse. Colocalization of CD31 with S100A4/FSP-1 and α-SMA expression in coronary arterioles is shown in yellow. DAPI (Blue) was used to stain nucleus. Scale bars=40 μm. B. and C. Representative z-stack image analysis shows specific overlay of double immunostaining, CD31+/S100A4+ cells in specific ordinate were analyzed in z stack with optimal interval range of 0.8μm. D. and E. The percentage of S100A4+ CD31+ cells and α-SMA+ CD31+ cells in diabetic hearts. F–I. RT-PCR analysis shows CD31, VE-Cadherin, FSP-1 and α-SMA in sorted cardiac endothelial cells by magnetic affinity cell sorting using a CD146 antibody. Data are mean ± SEM. *p<0.05 compared with control; #p<0.05 compared with vehicle treatment group. n=12 mice for each group.

Article Snippet: Endothelial cells were isolated using positive selection by magnetic affinity cell sorting using a CD146 antibody (Miltenyi Biotec) and were then used for RNA isolation and RT-PCR.

Techniques: Double Immunofluorescence Staining, Expressing, Staining, Double Immunostaining, Reverse Transcription Polymerase Chain Reaction, FACS, Control

Journal: Chemistry & Biodiversity

Article Title: CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer

doi: 10.1002/cbdv.202501618

Figure Lengend Snippet: Protein and gene expression levels of CA IX, Caspase‐3 (CAS‐3), Vimentin (VIM), and E‐Cadherin (E‐CAD) across groups. The data were presented as mean ± SD ( n = 10). * p < 0.05 and ** p < 0.01 represent significance for comparisons between tumor (T) and normal breast (N) tissues.

Article Snippet: Protein levels of CA IX (Catalog No: E‐EL‐M0227, Elabscience), Vimentin (Catalog No: E2669Mo, BT Lab), E‐Cadherin (Catalog No: E‐EL‐M0211), and Caspase‐3 (Catalog No: E‐EL‐M0238) were determined using ELISA kits, following the manufacturer's protocols.

Techniques: Gene Expression

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential

doi: 10.1161/atvbaha.110.213751

Figure Lengend Snippet: Figure 4. DKK1 increases neovascularization in vivo. A, Matrigel plugs in C57/Bl6J wild-type mice with basic fibroblast growth factor (bFGF). B, Matrigel plugs in C57/Bl6J wild-type mice with bFGF and DKK1, 100 ng per plug. C, Quantification of hemoglobin content in plugs. D, Quantification of sVEGFR2 level in plugs. E, Tumor growth curves of HBCx-12 breast cancer xenograft as a function of time, peritumorally treated with DKK1 (100 ng) or control vehicle. F, Many mouse blood vessels at the tumor periphery stain positive for CD31 (red) in breast cancer xenografts treated with DKK1 (right) in contrast to a nontreated xenograft (left). The human carcinoma cell membrane is stained with EpCAM (green). The scale bar indicates 100 m.

Article Snippet: Tumors sections were stained at room temperature for 1h with anti-human EpCAM (clone HEA-125) fluorescein isothiocyanate (Miltenyi-Biotec SAS, Paris, France) and anti-mouse CD31 (BD Pharmingen, Evry, France) in PBS followed by an incubation with anti-rat Alexa-Fluor®555 secondary antibody (Invitrogen-Molecular Probes, Cergy Pontoise, France) for 30 minutes.

Techniques: In Vivo, Control, Staining, Membrane